Sintx Technologies, Inc. (SINT)
NASDAQ: SINT · Real-Time Price · USD
2.420
0.00 (0.00%)
May 5, 2026, 4:00 PM EDT - Market closed
Sintx Technologies Revenue
In the year 2025, Sintx Technologies had annual revenue of $1.02M, down -64.74%. Sintx Technologies had revenue of $290.00K in the quarter ending December 31, 2025, a decrease of -46.49%.
Revenue (ttm)
$1.02M
Revenue Growth
-64.74%
P/S Ratio
9.80
Revenue / Employee
$31,813
Employees
32
Market Cap
9.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.02M | -1.87M | -64.74% |
| Dec 31, 2024 | 2.89M | 260.00K | 9.90% |
| Dec 31, 2023 | 2.63M | 1.07M | 68.29% |
| Dec 31, 2022 | 1.56M | 955.00K | 157.59% |
| Dec 31, 2021 | 606.00K | 12.00K | 2.02% |
| Dec 31, 2020 | 594.00K | -95.00K | -13.79% |
| Dec 31, 2019 | 689.00K | 594.00K | 625.26% |
| Dec 31, 2018 | 95.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 15.23M | -4.23M | -21.73% |
| Dec 31, 2015 | 19.45M | -3.31M | -14.55% |
| Dec 31, 2014 | 22.77M | 451.00K | 2.02% |
| Dec 31, 2013 | 22.31M | -751.00K | -3.26% |
| Dec 31, 2012 | 23.07M | 2.80M | 13.84% |
| Dec 31, 2011 | 20.26M | 20.17M | 21,261.62% |
| Dec 31, 2006 | 94.85K | 25.64K | 37.05% |
| Dec 31, 2005 | 69.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 52.68M |
| Trinity Biotech | 43.79M |
| Vivos Therapeutics | 17.44M |
| Beyond Air | 6.92M |
| Biomerica | 4.33M |
| Tenon Medical | 3.94M |
| Co-Diagnostics | 622.49K |
| iTonic Holdings | 523.03K |
SINT News
- 6 weeks ago - SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution - GlobeNewsWire
- 6 weeks ago - SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant - GlobeNewsWire
- 2 months ago - SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms - GlobeNewsWire
- 3 months ago - SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5 - GlobeNewsWire
- 5 months ago - SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants - GlobeNewsWire
- 6 months ago - SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System - GlobeNewsWire
- 7 months ago - SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System - GlobeNewsWire
- 7 months ago - SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics - GlobeNewsWire